Sunday, 13 September 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

NEW SOURCES ENERGY Stock Impressive Jump On Tuesday, Outperforms Market

Loading stream...

(VIANEWS) - The Market ended the session with NEW SOURCES ENERGY (NSE.AS) jumping 11.11% to €0.03 on Tuesday, after two successive sessions in a row of losses. AEX-Index fell 0.04% to €881.42, after five successive sessions in a row of gains, on what was a somewhat negative trend exchanging session today.

NEW SOURCES ENERGY's last close was €0.02, 62.5% below its 52-week high of €0.06.

About NEW SOURCES ENERGY

Yearly Top and Bottom Value

NEW SOURCES ENERGY's stock is valued at €0.03 at 22:33 EST, way below its 52-week high of €0.06 and way above its 52-week low of €0.01.

Volume

Today's last reported volume for NEW SOURCES ENERGY is 34000 which is 61.68% below its average volume of 88732.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NEW SOURCES ENERGY's stock is considered to be overbought (>=80).

More news about NEW SOURCES ENERGY (NSE.AS).

Categories

stockMarket

Tags

Market-Close NowStock PriceClosesStock Market NowEnd of DayPrice UpMarket CloseStock Price UpNSE.ASNEW SOURCES ENERGYStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Keeps Flowing as Enterprise Adoption and Government Contracts Validate the Bet
A late-August surge of nine-figure funding rounds (Socure, Stability AI, Generalist AI, Gatik, Regent Craft, Emerald AI, Owner) shows venture capital still pouring into AI infrastructure, identity/fintech, and autonomy, even as public-market sentiment stays jumpy — Palantir's stock fell 6% the same week it landed the Army's TITAN contract. UiPath's raised guidance and strong Q2 results, alongside efficiency breakthroughs like Multiverse Computing's model compression, point to real enterprise monetization catching up to the funding hype.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com